3-CMC Stats & Data

3‑CMC has been recognised by EU authorities as a harmful new psychoactive substance; EMCDDA/EUDA conducted a formal risk assessment in 2021, leading to EU‑wide control in 2022. Multiple fatal and non‑fatal intoxications have been reported, commonly with polydrug use. Because it is short‑acting, compulsive redosing is frequently described, which increases acute risks such as hypertension, hyperthermia, agitation, and insomnia. Drug‑checking services repeatedly warn that powders or pills sold as “3‑MMC” or “MDMA” often contain 3‑CMC or mixtures; always test if possible and begin with a small allergy dose when identity is uncertain. 3‑CMC and its isomer iso‑3‑CMC have both been found in the market; iso‑3‑CMC’s toxicity is poorly characterised, and 3‑CMC may degrade to isomeric/by‑products, particularly in solution—avoid pre‑dissolving for storage and keep material dry, cool, and protected from light. Nasal use can be harsh and may increase compulsion to redose; spacing doses and planning a hard stop time reduces harm. Combining with MAOIs, tramadol, or high‑dose serotonergics can precipitate serotonin toxicity (agitation, clonus, hyperthermia); seek urgent care if these occur. For parties or hot environments, avoid overheating: take regular cool‑down breaks, sip electrolytes, and do not overhydrate. Aftercare (sleep, calories, fluids) mitigates ‘cath‑flu’ dysphoria. Avoid driving and hazardous tasks until fully baseline.